Differences in the Immune Response of the Nonmetastatic Axillary Lymph Nodes between Triple-Negative and Luminal A Breast Cancer Surrogate Subtypes
- PMID: 33309504
- DOI: 10.1016/j.ajpath.2020.11.008
Differences in the Immune Response of the Nonmetastatic Axillary Lymph Nodes between Triple-Negative and Luminal A Breast Cancer Surrogate Subtypes
Abstract
Breast cancer (BC) comprises four immunohistochemical surrogate subtypes of which triple-negative breast cancer (TNBC) has the highest risk of mortality. Axillary lymph nodes (ALNs) are the regions where BC cells first establish before distant metastasis, and the presence of tumor cells in the ALN causes an immune tolerance profile that contrasts with that of the nonmetastatic ALN (ALN-). However, few studies have compared the immune components of the ALNs- in BC subtypes. The present study aimed to determine whether differences between immune populations in the primary tumor and ALNs- were associated with the luminal A or TNBC subtype. We evaluated a retrospective cohort of 144 patients using paraffin-embedded biopsies. The TNBC samples tended to have a higher histologic grade and proliferation index and had higher levels of immune markers compared with luminal A in primary tumors and ALNs-. Two methods for validating the multivariate analysis found that histologic grade, intratumoral S100 dendritic cells, and CD8 T lymphocytes and CD57 natural killer cells in the ALNs- were factors associated with TNBC, whereas CD83 dendritic cells in the ALNs- were associated with the luminal A subtype. In conclusion, we found that intratumoral regions and ALNs- of TNBC contained higher concentrations of markers related to immune tolerance than luminal A. This finding partially explains the worse prognosis of patients with TNBC.
Copyright © 2021 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.
Similar articles
-
CD68 and CD83 immune populations in non-metastatic axillary lymph nodes are of prognostic value for the survival and relapse of breast cancer patients.Breast Cancer. 2022 Jul;29(4):618-635. doi: 10.1007/s12282-022-01336-2. Epub 2022 Feb 8. Breast Cancer. 2022. PMID: 35137329
-
Postmastectomy radiotherapy benefit in Chinese breast cancer patients with T1-T2 tumor and 1-3 positive axillary lymph nodes by molecular subtypes: an analysis of 1369 cases.Tumour Biol. 2016 May;37(5):6465-75. doi: 10.1007/s13277-015-4546-0. Epub 2015 Dec 2. Tumour Biol. 2016. PMID: 26631044
-
Merits of Level III Axillary Dissection in Node-Positive Breast Cancer: A Prospective, Single-Institution Study From India.J Glob Oncol. 2019 Feb;5:1-8. doi: 10.1200/JGO.18.00165. J Glob Oncol. 2019. PMID: 30811304 Free PMC article.
-
Intrinsic subtype and immunity score in identification of triple-negative breast cancer at low risk.Breast. 2025 Apr;80:103889. doi: 10.1016/j.breast.2025.103889. Epub 2025 Jan 23. Breast. 2025. PMID: 39908962 Free PMC article.
-
Immune response profile of primary tumour, sentinel and non-sentinel axillary lymph nodes related to metastasis in breast cancer: an immunohistochemical point of view.Histochem Cell Biol. 2019 Sep;152(3):177-193. doi: 10.1007/s00418-019-01802-7. Epub 2019 Jul 13. Histochem Cell Biol. 2019. PMID: 31300877 Review.
Cited by
-
Dendritic Cell Subpopulations Are Associated with Morphological Features of Breast Ductal Carcinoma In Situ.Int J Mol Sci. 2023 Jun 8;24(12):9918. doi: 10.3390/ijms24129918. Int J Mol Sci. 2023. PMID: 37373062 Free PMC article.
-
Prognostic Implications of the Residual Tumor Microenvironment after Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Patients without Pathological Complete Response.Cancers (Basel). 2023 Jan 18;15(3):597. doi: 10.3390/cancers15030597. Cancers (Basel). 2023. PMID: 36765559 Free PMC article.
-
Extensive review on breast cancer its etiology, progression, prognostic markers, and treatment.Med Oncol. 2023 Jul 14;40(8):238. doi: 10.1007/s12032-023-02111-9. Med Oncol. 2023. PMID: 37442848 Review.
-
CD68 and CD83 immune populations in non-metastatic axillary lymph nodes are of prognostic value for the survival and relapse of breast cancer patients.Breast Cancer. 2022 Jul;29(4):618-635. doi: 10.1007/s12282-022-01336-2. Epub 2022 Feb 8. Breast Cancer. 2022. PMID: 35137329
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials